Evidence Level
Phosphatidylcholine has an extensive evidence base, particularly for alcoholic liver disease. Lieber et al. (1990) published landmark research showing PPC prevented cirrhosis in alcohol-fed baboons. The large Veterans Affairs Cooperative Study (Lieber et al., 2003, n=789) evaluated PPC in human alcoholic liver disease over 2 years, finding trends toward reduced fibrosis, though the primary endpoint was not fully met due to high dropout rates. Gundermann et al. (2016) conducted the most comprehensive review to date, analyzing 85 clinical studies involving over 6,000 NAFLD and ALD patients and finding consistent improvements in liver enzymes and ultrasonographic findings. PPC (as Essentiale) is one of the most widely prescribed hepatoprotective agents worldwide, particularly in Europe and Asia.